Viewing Study NCT01363232

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:57 PM
Ignite Modification Date: 2026-03-29 @ 3:01 PM
Study NCT ID: NCT01363232
Status: COMPLETED
Last Update Posted: 2020-10-05
First Post: 2011-05-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumors View
None Selected Solid Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BKM120 View
None MEK162 View
None RAS RAF mutations View
None triple negative breast cancer View
None pancreatic cancer, ovarian cancer View
None NSCLC progressed on EGFR TKI View
None PI3K inhibitor View
None MEK inhibitor View